Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: Single-institution study

Yosh Maruyama; J. R. Van Nagell; Justine Yoneda; Elvis Donaldson; Holly Gallion; Robert Higgins; Deborah Powell; Carol Turner; Richard Kryscio

doi:10.1093/jnci/80.7.501

Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: Single-institution study

Yosh Maruyama, J. R. Van Nagell, Justine Yoneda, Elvis Donaldson, Holly Gallion, Robert Higgins, Deborah Powell, Carol Turner, Richard Kryscio

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

A fast-neutron-emitting radioisotope, ²⁵²Cf, is being tested in clinical trials of neutron brachytherapy for cervical cancer. The efficacy for histological eradication of bulky stage IB cervical tumors (mean diameter, ∼6 cm) using combined radiation and surgery was studied in 65 patients treated with ¹³⁷Cs or ²⁵²Cf before surgery during 1983-1986. Forty-four patients were treated with ¹³⁷Cs and 21 were treated with ²⁵²Cf at equivalent doses of radiation. Fifteen of the 44 specimens (34%) were positive after ¹³⁷Cs therapy. Only one of the 21 specimens was positive after ²⁵²Cf therapy (P = .025), and that patient was treated in a delayed schedule 21 days after the start of external-beam irradiation rather than early in the course. ²⁵²Cf therapy required a much lower radiation dose and shorter treatment time. The study compared tumor destruction of an identically staged human cervical tumor in situ by direct histological means, using ²⁵²Cf neutron therapy or conventional photon therapy at an identical and equivalent dose adjusted by a relative biological effectiveness of 6.0 for ²⁵²Cf.

Original language	English
Pages (from-to)	501-506
Number of pages	6
Journal	Journal of the National Cancer Institute
Volume	80
Issue number	7
DOIs	https://doi.org/10.1093/jnci/80.7.501
State	Published - Jun 1 1988

Bibliographical note

Funding Information:
1Received December 17, 1987; revised March 24, 1988; accepted March 25, 1988. 2Supported by research grant PDT-222B from the American Cancer Society. 3 The 252Cf was obtained by contract from the U.S. Department of Energy. 4Departments of Radiation Medicine (Y. Maruyama, J. Yoneda, C. Turner), Obstetrics and Gynecology (J. R. van Nagell, E Donaldson, H. Gal-lion, R. Higgins), Pathology (D. Powell), and Statistics {R Kryscio), Radiation Therapy Oncology Center, University of Kentucky Medical Center, Lexington, KY. 3 We thank Dr. D. Y. Hou, Ann Martin, Shartene West, and L. C. Wilson for their assistance in these studies and Angela Sandifer for expert clerical assistance. * Correspondence to: Yosh Maruyama, M.D., Department of Radiation Medicine, University of Kentucky Medical Center, 800 Rose St, Lexington, KY 40536.

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/80.7.501

Cite this

Maruyama, Y., Van Nagell, J. R., Yoneda, J., Donaldson, E., Gallion, H., Higgins, R., Powell, D., Turner, C., & Kryscio, R. (1988). Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: Single-institution study. Journal of the National Cancer Institute, 80(7), 501-506. https://doi.org/10.1093/jnci/80.7.501

@article{f743443765c847a9b35a5083470b4d61,

title = "Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: Single-institution study",

abstract = "A fast-neutron-emitting radioisotope, 252Cf, is being tested in clinical trials of neutron brachytherapy for cervical cancer. The efficacy for histological eradication of bulky stage IB cervical tumors (mean diameter, ∼6 cm) using combined radiation and surgery was studied in 65 patients treated with 137Cs or 252Cf before surgery during 1983-1986. Forty-four patients were treated with 137Cs and 21 were treated with 252Cf at equivalent doses of radiation. Fifteen of the 44 specimens (34%) were positive after 137Cs therapy. Only one of the 21 specimens was positive after 252Cf therapy (P = .025), and that patient was treated in a delayed schedule 21 days after the start of external-beam irradiation rather than early in the course. 252Cf therapy required a much lower radiation dose and shorter treatment time. The study compared tumor destruction of an identically staged human cervical tumor in situ by direct histological means, using 252Cf neutron therapy or conventional photon therapy at an identical and equivalent dose adjusted by a relative biological effectiveness of 6.0 for 252Cf.",

author = "Yosh Maruyama and {Van Nagell}, {J. R.} and Justine Yoneda and Elvis Donaldson and Holly Gallion and Robert Higgins and Deborah Powell and Carol Turner and Richard Kryscio",

note = "Funding Information: 1Received December 17, 1987; revised March 24, 1988; accepted March 25, 1988. 2Supported by research grant PDT-222B from the American Cancer Society. 3 The 252Cf was obtained by contract from the U.S. Department of Energy. 4Departments of Radiation Medicine (Y. Maruyama, J. Yoneda, C. Turner), Obstetrics and Gynecology (J. R. van Nagell, E Donaldson, H. Gal-lion, R. Higgins), Pathology (D. Powell), and Statistics {R Kryscio), Radiation Therapy Oncology Center, University of Kentucky Medical Center, Lexington, KY. 3 We thank Dr. D. Y. Hou, Ann Martin, Shartene West, and L. C. Wilson for their assistance in these studies and Angela Sandifer for expert clerical assistance. * Correspondence to: Yosh Maruyama, M.D., Department of Radiation Medicine, University of Kentucky Medical Center, 800 Rose St, Lexington, KY 40536.",

year = "1988",

month = jun,

day = "1",

doi = "10.1093/jnci/80.7.501",

language = "English",

volume = "80",

pages = "501--506",

number = "7",

}

Maruyama, Y, Van Nagell, JR, Yoneda, J, Donaldson, E, Gallion, H, Higgins, R, Powell, D, Turner, C & Kryscio, R 1988, 'Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: Single-institution study', Journal of the National Cancer Institute, vol. 80, no. 7, pp. 501-506. https://doi.org/10.1093/jnci/80.7.501

Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: Single-institution study. / Maruyama, Yosh; Van Nagell, J. R.; Yoneda, Justine et al.
In: Journal of the National Cancer Institute, Vol. 80, No. 7, 01.06.1988, p. 501-506.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer

T2 - Single-institution study

AU - Maruyama, Yosh

AU - Van Nagell, J. R.

AU - Yoneda, Justine

AU - Donaldson, Elvis

AU - Gallion, Holly

AU - Higgins, Robert

AU - Powell, Deborah

AU - Turner, Carol

AU - Kryscio, Richard

N1 - Funding Information: 1Received December 17, 1987; revised March 24, 1988; accepted March 25, 1988. 2Supported by research grant PDT-222B from the American Cancer Society. 3 The 252Cf was obtained by contract from the U.S. Department of Energy. 4Departments of Radiation Medicine (Y. Maruyama, J. Yoneda, C. Turner), Obstetrics and Gynecology (J. R. van Nagell, E Donaldson, H. Gal-lion, R. Higgins), Pathology (D. Powell), and Statistics {R Kryscio), Radiation Therapy Oncology Center, University of Kentucky Medical Center, Lexington, KY. 3 We thank Dr. D. Y. Hou, Ann Martin, Shartene West, and L. C. Wilson for their assistance in these studies and Angela Sandifer for expert clerical assistance. * Correspondence to: Yosh Maruyama, M.D., Department of Radiation Medicine, University of Kentucky Medical Center, 800 Rose St, Lexington, KY 40536.

PY - 1988/6/1

Y1 - 1988/6/1

N2 - A fast-neutron-emitting radioisotope, 252Cf, is being tested in clinical trials of neutron brachytherapy for cervical cancer. The efficacy for histological eradication of bulky stage IB cervical tumors (mean diameter, ∼6 cm) using combined radiation and surgery was studied in 65 patients treated with 137Cs or 252Cf before surgery during 1983-1986. Forty-four patients were treated with 137Cs and 21 were treated with 252Cf at equivalent doses of radiation. Fifteen of the 44 specimens (34%) were positive after 137Cs therapy. Only one of the 21 specimens was positive after 252Cf therapy (P = .025), and that patient was treated in a delayed schedule 21 days after the start of external-beam irradiation rather than early in the course. 252Cf therapy required a much lower radiation dose and shorter treatment time. The study compared tumor destruction of an identically staged human cervical tumor in situ by direct histological means, using 252Cf neutron therapy or conventional photon therapy at an identical and equivalent dose adjusted by a relative biological effectiveness of 6.0 for 252Cf.

AB - A fast-neutron-emitting radioisotope, 252Cf, is being tested in clinical trials of neutron brachytherapy for cervical cancer. The efficacy for histological eradication of bulky stage IB cervical tumors (mean diameter, ∼6 cm) using combined radiation and surgery was studied in 65 patients treated with 137Cs or 252Cf before surgery during 1983-1986. Forty-four patients were treated with 137Cs and 21 were treated with 252Cf at equivalent doses of radiation. Fifteen of the 44 specimens (34%) were positive after 137Cs therapy. Only one of the 21 specimens was positive after 252Cf therapy (P = .025), and that patient was treated in a delayed schedule 21 days after the start of external-beam irradiation rather than early in the course. 252Cf therapy required a much lower radiation dose and shorter treatment time. The study compared tumor destruction of an identically staged human cervical tumor in situ by direct histological means, using 252Cf neutron therapy or conventional photon therapy at an identical and equivalent dose adjusted by a relative biological effectiveness of 6.0 for 252Cf.

UR - http://www.scopus.com/inward/record.url?scp=0023915610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023915610&partnerID=8YFLogxK

U2 - 10.1093/jnci/80.7.501

DO - 10.1093/jnci/80.7.501

M3 - Article

C2 - 3367388

AN - SCOPUS:0023915610

SN - 0027-8874

VL - 80

SP - 501

EP - 506

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 7

ER -

Efficacy of brachytheraphy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: Single-institution study

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this